Vivo Opportunity, LLC purchased $32K of INM (indirect holdings)
Vivo Opportunity, LLC purchased 20,546 indirectly-held shares of InMed Pharmaceuticals Inc. (INM) at $1.55 across 6 trades over 2026-07-14 to 2026-07-16.
How this was made
The 30-second read
Why it matters
The newest information is the specific open-market purchase details (shares, price, dates) by Vivo Opportunity, LLC, an entity tied to a 10% owner role, increasing indirect holdings to 75,019 shares.
Market read
Traders may treat this as a small, incremental bullish signal, but it is unlikely to drive a major repricing without additional fundamental catalysts.
What to watch
No 10b5-1 plan is cited, but the filing does not explain intent, liquidity constraints, or whether the purchase is part of a broader accumulation strategy.
Background
The article is an SEC Form 4 insider transaction disclosure for InMed Pharmaceuticals Inc. (INM).
Ticker impact
InMed Pharmaceuticals disclosed a Vivo Opportunity, LLC indirect open-market purchase of 20,546 shares at $1.55 from July 14-16, 2026.
Likely limited, short-lived sentiment lift; no clear directional signal beyond incremental insider/affiliate buying.
The filing is primary-source and time-stamped, but the transaction size is small ($31.8k) and there is no accompanying guidance, trial result, or corporate action.
Market effects
Minimal; this is company-specific insider/affiliate buying with no sector-wide datapoint.
None indicated.
None indicated.
Counterpoint
Indirect holdings and small dollar value may reflect routine portfolio rebalancing rather than a strong conviction signal.
Key entities
- issuerInMed Pharmaceuticals Inc.
Company whose shares were purchased; subject of the Form 4 disclosure.
- reporterVivo Opportunity, LLC
10% owner-related entity that executed the indirect open-market purchases.
